Puma Biotechnology Inc (NASDAQ:PBYI)’s share price was down 1% on Tuesday . The stock traded as low as $91.10 and last traded at $98.85. Approximately 531,200 shares traded hands during trading, a decline of 50% from the average daily volume of 1,065,333 shares. The stock had previously closed at $99.80.

Several equities analysts have recently weighed in on PBYI shares. Stifel Nicolaus lifted their price objective on Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 2nd. Citigroup reiterated a “buy” rating and set a $164.00 price objective on shares of Puma Biotechnology in a report on Wednesday. Credit Suisse Group reiterated an “outperform” rating and set a $136.00 price objective on shares of Puma Biotechnology in a report on Wednesday, September 27th. ValuEngine cut Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, BidaskClub upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $130.67.

The company has a market cap of $3,477.11, a P/E ratio of -11.76 and a beta of 0.72.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the previous year, the firm posted ($1.11) EPS. analysts anticipate that Puma Biotechnology Inc will post -8.19 earnings per share for the current year.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 21.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PBYI. Schwab Charles Investment Management Inc. increased its position in shares of Puma Biotechnology by 3.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 123,380 shares of the biopharmaceutical company’s stock worth $10,784,000 after purchasing an additional 4,068 shares during the last quarter. Rhumbline Advisers increased its position in shares of Puma Biotechnology by 0.8% during the 2nd quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock worth $2,948,000 after purchasing an additional 271 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Puma Biotechnology by 1.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 136,297 shares of the biopharmaceutical company’s stock worth $11,912,000 after purchasing an additional 2,072 shares during the last quarter. Legal & General Group Plc increased its position in shares of Puma Biotechnology by 12.8% during the 2nd quarter. Legal & General Group Plc now owns 10,490 shares of the biopharmaceutical company’s stock worth $918,000 after purchasing an additional 1,193 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in shares of Puma Biotechnology during the 2nd quarter worth approximately $262,000. Hedge funds and other institutional investors own 96.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was published by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.mareainformativa.com/puma-biotechnology-pbyi-shares-down-1/120814/.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.